Epigral Reports 868.9 Million Rupees Profit in Q4, Revenue Reaches 6.28 Billion Rupees

Epigral Ltd has announced its financial results for the March quarter, reporting a consolidated net profit of 868.9 million rupees. The company also recorded a total revenue from operations of 6.28 billion rupees, reflecting steady performance in its specialty chemicals and derivatives business.  

In addition to its earnings report, Epigral has declared a dividend of 3.5 rupees per share, reinforcing its commitment to shareholder returns. The company has been focusing on expanding its production capacity and optimizing costs to sustain profitability.  

Epigral has maintained a stable financial trajectory, leveraging strong demand and operational efficiencies to drive growth. The latest results highlight its position as a key player in the specialty chemicals sector, with continued efforts to enhance product offerings and market reach.  

Financial overview:  
- Epigral Ltd reports 868.9 million rupees consolidated net profit for Q4  
- Revenue from operations reaches 6.28 billion rupees, reflecting stable performance  
- Declares a dividend of 3.5 rupees per share, reinforcing shareholder returns  
- Strong demand and cost optimization contribute to revenue growth  

Sources: Economic Times, Business Standard, Moneycontrol